Bowel Cleansers, XIFAXAN([R]) and Other Product Revenue Increases 34% Over 2006
Q4 and Full Year 2007 Financial Results Impacted by $34.6 Million Non-Cash Charge Related to Introduction of Generic Balsal…
The final part of this series covers the use of infliximab, anticholinergics/antispasmodics, gastrointestinal stimulants, and anorectal preparations in pregnant and lactating women.
* Infliximab (Remicade): Infliximab is a monoclonal antibody used to treat severe Crohn’s disease and au…
The Center for Constitutional Litigation (CCL) has achieved another victory against arguments that FDA labeling regulations preempt state failure-to-warn claims. (Kelly v. Wyeth, 2007 WL 1302589 (Mass. Super. Apr. 12, 2007) .)
Related Results
…
ROCKVILLE, MD. — At a meeting last month, members of the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee agreed that the risk of tardive dyskinesia associated with the metoclopramide component of a fixed-dose combina…
Tourette’s disorder, with a prevalence of 1% to 3% of children and adolescents (Robertson, 2003), is a chronic, childhood-onset neuropsychiatric illness. It is characterized by motor and vocal tics that fluctuate…
Background & objectives: Delayed emesis with cisplatin is a significant problem, which is often poorly controlled with conventional antiemetics. There is a relative paucity of data on the control of delayed emesis and rather inconsistent results have been reported. The present study aimed to compare the efficacy and tolerability of ondansetron versus metoclopramide in dose related grades of cisplatin-induced delayed emesis.
…
Zydis([R]) Technology Provides Fast-Dissolving, Patient-Friendly Formulation
Related Results
POZEN Receives Approval for MT 100 in the …
